Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML patient cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below).

Each clinical case will be forwarded to the iCMLf expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are only accepted from clinicians. If individual patients have a specific question we encourage them to contact their healthcare provider.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

TFR following presentation in CML - AP

  • Dr. Saurabh Bhave
  • Dr. Saurabh Bhave's Avatar Topic Author
6 months 2 weeks ago #1735 by Dr. Saurabh Bhave
TFR following presentation in CML - AP was created by Dr. Saurabh Bhave
Dear Team,

20 year old male

diagnosed as CML in AP in January 2017

no comorbidities

Started on Dasatinib 140 mg /day

His RQ-PCR is 0 % since last 2 years

Is he a candidate for TRF ? If yes when ?

Regards

Dr.Saurabh Bhave
Tata Medical Center, Kolkata
  • Dr. Francisco Cervantes
  • Dr. Francisco Cervantes's Avatar Topic Author
6 months 2 weeks ago - 6 months 2 weeks ago #1736 by Dr. Francisco Cervantes
Replied by Dr. Francisco Cervantes on topic TFR following presentation in CML - AP
The general agreement for patients whose AP is the form of presentation of CML is to go on with the TKI indefinitely if they achieve a good response, as it is the case with this patient. Given the patient’s high risk because of his CML phase, TKI discontinuation is not recommended, and treatment should be given indefinitely. One possibility would be to reduce dasatinib dose to 100 mg daily, taking into account the sustained good molecular response.

ORIGINAL CASE:
20 year old male
diagnosed as CML in AP in January 2017
no comorbidities
Started on Dasatinib 140 mg /day
His RQ-PCR is 0 % since last 2 years
Is he a candidate for TRF ? If yes when ?
Last edit: 6 months 2 weeks ago by Nicola.
Moderators: Melissa Davis-Bishop